Uploaded November 2025 | Updated September 2026, 1 week ago
You can view Dr. Gombolay's presentation slides here:
files.wearesrna.org/symposia/2025_rnds/slides/2025RNDS-Research_Emory_Atlanta-Grace_Gombolay.pdf
In this session of the 2025 RNDS, Drs. Grace Gombolay, Varun Kannan, and Spencer Hutto of Emory University discussed current and prospective research at their facility. Some of the research topics include the efficacy of IVIG as a long-term treatment for MOGAD and PLEX as a short-term treatment, which diets are best for people with rare neuroimmune disorders, the capacity for early differentiation in disorders through MRI imaging, MRI techniques to examine blood-brain barrier injury, and leptomeningeal enhancement in MOGAD.
Future work includes utilizing AI to help with earlier diagnosis, creating an international treatment consensus for MOGAD, and understanding predictive markers. They are currently seeking to create a patient registry, collecting blood and cerebro-spinal fluid to look for biomarkers for relapse. Audience members asked questions about the glymphatic system, funding clinical research, and how patients and advocacy organizations can get involved.
You can view Dr. Gombolay's presentation slides here:
files.wearesrna.org/symposia/2025_rnds/slides/2025RNDS-Research_Emory_Atlanta-Grace_Gombolay.pdf
In this session of the 2025 RNDS, Drs. Grace Gombolay, Varun Kannan, and Spencer Hutto of Emory University discussed current and prospective research at their facility. Some of the research topics include the efficacy of IVIG as a long-term treatment for MOGAD and PLEX as a short-term treatment, which diets are best for people with rare neuroimmune disorders, the capacity for early differentiation in disorders through MRI imaging, MRI techniques to examine blood-brain barrier injury, and leptomeningeal enhancement in MOGAD.
Future work includes utilizing AI to help with earlier diagnosis, creating an international treatment consensus for MOGAD, and understanding predictive markers. They are currently seeking to create a patient registry, collecting blood and cerebro-spinal fluid to look for biomarkers for relapse. Audience members asked questions about the glymphatic system, funding clinical research, and how patients and advocacy organizations can get involved.
